Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors
August 13 2020 - 3:08PM
Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a
global leader in molecular diagnostics and precision medicine,
today announced the appointment of Paul J. Diaz as
President and Chief Executive Officer, effective August 13, 2020.
He will also serve on the Company’s Board of Directors. Mr. Diaz
brings to Myriad Genetics more than three decades of
executive leadership and business transformation experience in
healthcare across a variety of healthcare segments.
“Paul is an exceptional leader and executive with extraordinary
passion, vision, experience, and operational skills,” said S.
Louise Phanstiel, Chair of Myriad’s Board of Directors. “His
focus on building high performing teams, and instilling a culture
that empowers people to deliver high quality patient care,
distinctive customer service and innovation, will be important to
supporting Myriad’s mission and growth. We are excited to
have Paul assume the leadership of Myriad Genetics and chart the
course to realize the Company’s full potential. We look forward to
officially introducing Paul during our fourth quarter earnings
call. Myriad is dedicated to providing vital information to
physicians, patients and their families that enables them to make
better decisions about their health and treatment planning.
Paul’s personal dedication, throughout his career, to patients and
their care will be critical in advancing Myriad’s vision of being a
trusted advisor transforming patients’ lives worldwide with
pioneering molecular diagnostics.”
“I am very excited to join the talented management team and
Board of Directors of Myriad Genetics, an organization dedicated to
helping patients and physicians identify the risk of developing
disease and accurately diagnosing disease and disease progression,”
commented Paul. “Our goal is to empower patients, as
consumers, and their physicians and our payer partners with the
information and data to help guide their treatment decisions, to
improve clinical outcomes and lower healthcare costs. I
am equally excited about Myriad’s potential for innovation and
growth. The Company has a tremendous opportunity to
transform its business, and strategically position itself for
sustainable, profitable growth. We will look to leverage the
company’s culture of innovation and revitalize our approach to the
commercializing of its products and customer service levels.“
Mr. Diaz served as the President and Chief Executive Officer and
Executive Director and Director of Kindred Healthcare, Inc. for
over ten years, where he led the growth, revitalization and
diversification of the business that positioned Kindred as the
largest provider of post-acute health care services in the United
States. Most recently, Mr. Diaz was a Partner at Cressey
& Company LP, a private equity firm focusing on healthcare
services and HCIT companies. Mr. Diaz is an experienced
director and operating executive, having served as an executive and
board member of multiple public and private companies. He
currently serves on the board of DaVita, Inc. (NYSE: DVA) and is a
member of the Board of Trustees of Johns Hopkins Medicine.
Mr. Diaz graduated from The American University with a B.S. in
Business Administration and with a J.D. from The Georgetown
University Law Center.
Heidrick & Struggles led the search process for Myriad.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements related to realizing the Company’s full potential;
officially introducing Paul during the Company’s fourth quarter
earnings call; advancing Myriad’s vision of being a trusted advisor
transforming patients’ lives worldwide with pioneering molecular
diagnostics; the Company’s potential for innovation and growth; the
Company’s tremendous opportunity to transform its business, and
strategically position itself for sustainable, profitable growth;
and the Company’s strategic directives under the caption "About
Myriad Genetics." These "forward-looking statements" are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: uncertainties
associated with COVID-19, including its possible effects on our
operations and the demand for our products and services; our
ability to efficiently and flexibly manage our business amid
uncertainties related to COVID-19; the risk that sales and profit
margins of our molecular diagnostic tests and pharmaceutical and
clinical services may decline; risks related to our ability to
transition from our existing product portfolio to our new tests,
including unexpected costs and delays; risks related to decisions
or changes in governmental or private insurers’ reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566
U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics,
Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573
U.S. 208 (2014); risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2020, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media Contact: |
Jared Maxwell
(801) 505-5027 jmaxwell@myriad.com |
|
Investor Contact: |
Scott
Gleason(801) 584-1143sgleason@myriad.com |
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jul 2023 to Jul 2024